2,959 research outputs found

    Open Source Information’s Blind Spot

    Get PDF
    Digital open source information has been heralded for its democratizing potential, insofar as it allows access to a much broader range of sources and voices than would normally be consulted through traditional methods of information gathering for international criminal investigations. It also helps to overcome some of the physical access barriers that are commonplace in international criminal investigations. At a time when the use of digital open source information is becoming more widespread, this article warns of the cognitive and technical biases that can impact upon two key stages of an investigation: finding relevant information and analysing that information. At the information-gathering stage, there are particular crimes, regions, and groups of people whose experiences are more likely to be overlooked or hidden in digital open source investigations. When it comes to analysing digital open source information, there is a danger that cognitive and technical biases may influence which information is deemed most relevant and useful to an international criminal investigation, and how that information is interpreted. This article proposes some steps that can be taken to mitigate these risks

    Enhancing Academic Achievement and Transition Outcomes Using Technology

    Get PDF
    This report was supported in whole or in part by the U.S. Department of Education, Office of Special Education Programs, (Cooperative Agreement No. H326J000005)

    Differentiating ‘the user’ in DSR: Developing demand side response in advanced economies

    Get PDF
    This paper reports on the current state of Demand Side Response (DSR) in the UK – an early adoptor amongst advanced economies – and the role of the end user in determining its future. Through 21 expert interviews we establish the current state of DSR, and expectations for its development. Whilst non-domestic DSR appears healthy, if fragile, domestic DSR is considered to be currently unviable, it's future success dependant on market innovations. In following how that situation is expected to change, we highlight key assumptions about prospective end users. These assumptions are shaping the efforts of the industry actors tasked with delivering DSR. We identify two visions of the user, one passive whilst technologies automate on their behalf, the other integrated to the point of themselves being an automaton. We detail a series of concerns about the limitations of these user visions, and the ability of industry to reach beyond them towards a more differentiated view. We conclude with a call to broaden the institutional landscape tasked with delivering DSR, in order to foster a greater diversity of end user roles, and ultimately greater demand responsiveness from a broader user base

    Smart grids, smart users? The role of the user in demand side management

    Get PDF
    Smart grids are a key feature of future energy scenarios, with the overarching goal of better aligning energy generation and demand. The work presented here considers the role of the user in such systems, and the contexts in which such roles might emerge. The data used is drawn from focus groups with 72 participants, using novel scenario techniques to contextualise smart grid technologies in domestic settings. Two contrasting visions of the smart grid are presented, a centralised system based on current institutional arrangements, and an alternative system in which decentralisation of generation and control is pursued. Using the concepts of ‘energy consumer’ and ‘energy citizen’, the paper considers what forms of engagement are likely to be generated by the two visions. We propose that smart grid designs must look beyond simply the technology and recognise that a smart user who is actively engaged with energy is critical to much of what is proposed by demand side management. We conclude that the energy citizen holds out most promise in this regard. The implications of this for policy makers are discussed

    Mapping the Use of Open Source Research in UN Human Rights Investigations

    Get PDF
    Open source information, particularly digital open source information that is publicly available on the internet, plays an increasingly central role in the landscape of human rights investigations. This article provides a thorough analysis of how open source information is used in practice by UN human rights fact-finding missions, commissions of inquiry and other official human rights investigations. Combining data from semi-structured interviews carried out with investigators with specific experience in open source human rights investigations with a review of reports and other primary and secondary sources, it examines the utility of open source information to UN human rights investigative bodies. It posits that open source research can offer tremendous benefits in planning investigations, supplying lead evidence, and providing direct evidence of violations, thereby overcoming some of the access barriers that investigators face, and potentially giving voice to a wider range of perspectives. On the other hand, this article argues that open source investigations should be approached with a clear eye to their challenges and possible pitfalls. These include the gaps of open source information and the potential to silence already-marginalized communities through open source investigations, as well as the resource-intensive nature of these investigations, the danger that open source information can affect witnesses’ perceptions, and the risks posed by online disinformation. As open source research is likely to comprise an important component of the human rights investigator’s toolbox in the future, this article argues in favour of the institutional buy-in, resourcing, and methodological rigour that it deserves

    Dumber energy at home please: Perceptions of Smart Energy Technologies are dependent on home, workplace, or policy context in the United Kingdom

    Get PDF
    Smart energy technologies (SETs) are being developed around the world to support using energy more efficiently and to smooth our consumption over time, helping us to meet our carbon reduction targets. Notably, SETs will only be effective with support and engagement from the public. Previous literature has focused on evaluating SETs within a residential context, however, results here may differ from a workplace or policy context. We note that surrogate decision making (SDM [1]) theory indicates we make decisions differently for others than for the self. Study one (N = 213) comprises a survey using a UK population sample that examines public perceptions and support for SETs in different contexts. Study two (N = 12) utilises interviews to explore perceptions in more depth, probing the nature of support using socio-cognitive constructs relating to SDM. We find that people are more likely to support SETs in a workplace or policy context, compared to residential contexts. In addition, we note that support for SETs is related to different socio-cognitive constructs in different contexts, and also that impulsivity of decision making differs across contexts. Decision making within workplace and policy contexts is characterised by higher levels of impulsivity than in a residential context, as well as a sense of shared responsibility. Our results indicate that translational research is needed when considering evidence based on residential studies in making decisions within workplace and policy contexts

    Digital energy visualisations in the workplace: the e-Genie tool

    Get PDF
    Building management systems are designed for energy managers; there are few energy feedback systems designed to engage staff. A tool, known as e-Genie, was developed to engage workplace occupants with energy data and support them to take action to reduce energy use. Building on research insights within the field, e-Genie’s novel approach encourages users to make plans to meet energy saving goals, supports discussion, and considers social energy behaviours (e.g. discussing energy issues, taking part in campaigns) as well as individual actions. A field based study of e-Genie indicated that visualisations of energy data were engaging and that the discussion ‘Pinboard’ was particularly popular. Pre- and post survey (N = 77) evaluation of users indicated that people were significantly more concerned about energy issues and reported engaging more in social energy behaviour after ~two weeks of e-Genie being installed. Concurrently, objective measures of electricity use decreased over the same period, and continued decreasing over subsequent weeks. Indications are that occupant facing energy feedback visualisations can be successful in reducing energy use in the workplace; furthermore supporting social energy behaviour in the workplace is likely to be a useful direction for promoting action

    Caught in the middle: the role of the facilities manager in organisational energy use

    Get PDF
    This study analyses the role of the Facilities Manager [FM] as a key actor in organisational energy management. This builds on the idea that ‘middle’ agents in networks can be an important lever for socio-technical change. The study demonstrates the considerable impact the FM can have on workplace energy consumption, whilst identifying a number of factors that constrain their agency and capacity to act. These include demands to meet workforce expectations of comfort; a lack of support from senior management; and a shortage of resources. Underlying these challenges, the study identifies three different energy rationales – that is to say conceptual frameworks – which are deployed by different groups of organisational actors. The challenges of reconciling these at-times-contradictory rationales results in a picture of energy management which to the outsider can appear highly irrational. The paper concludes with a consideration of how policy makers can apply these insights to support energy reduction in workplaces

    Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial.

    Get PDF
    BACKGROUND: Adjuvant chemotherapy for early breast cancer has improved outcomes but causes toxicity. The UK TACT2 trial used a 2×2 factorial design to test two hypotheses: whether use of accelerated epirubicin would improve time to tumour recurrence (TTR); and whether use of oral capecitabine instead of cyclophosphamide would be non-inferior in terms of patients' outcomes and would improve toxicity, quality of life, or both. METHODS: In this multicentre, phase 3, randomised, controlled trial, we enrolled patients aged 18 years or older from 129 UK centres who had histologically confirmed node-positive or high-risk node-negative operable breast cancer, had undergone complete excision, and were due to receive adjuvant chemotherapy. Patients were randomly assigned to receive four cycles of 100 mg/m2 epirubicin either every 3 weeks (standard epirubicin) or every 2 weeks with 6 mg pegfilgrastim on day 2 of each cycle (accelerated epirubicin), followed by four 4-week cycles of either classic cyclophosphamide, methotrexate, and fluorouracil (CMF; 600 mg/m2 cyclophosphamide intravenously on days 1 and 8 or 100 mg/m2 orally on days 1-14; 40 mg/m2 methotrexate intravenously on days 1 and 8; and 600 mg/m2 fluorouracil intravenously on days 1 and 8 of each cycle) or four 3-week cycles of 2500 mg/m2 capecitabine (1250 mg/m2 given twice daily on days 1-14 of each cycle). The randomisation schedule was computer generated in random permuted blocks, stratified by centre, number of nodes involved (none vs one to three vs four or more), age (≤50 years vs >50 years), and planned endocrine treatment (yes vs no). The primary endpoint was TTR, defined as time from randomisation to first invasive relapse or breast cancer death, with intention-to-treat analysis of standard versus accelerated epirubicin and per-protocol analysis of CMF versus capecitabine. This trial is registered with ISRCTN, number 68068041, and with ClinicalTrials.gov, number NCT00301925. FINDINGS: From Dec 16, 2005, to Dec 5, 2008, 4391 patients (4371 women and 20 men) were recruited. At a median follow-up of 85·6 months (IQR 80·6-95·9) no significant difference was seen in the proportions of patients free from TTR events between the accelerated and standard epirubicin groups (overall hazard ratio [HR] 0·94, 95% CI 0·81-1·09; stratified p=0·42). At 5 years, 85·9% (95% CI 84·3-87·3) of patients receiving standard epirubicin and 87·1% (85·6-88·4) of those receiving accelerated epirubicin were free from TTR events. 4358 patients were included in the per-protocol analysis, and no difference was seen in the proportions of patients free from TTR events between the CMF and capecitabine groups (HR 0·98, 95% CI 0·85-1.14; stratified p=0·00092 for non-inferiority). Compared with baseline, significantly more patients taking CMF than those taking capecitabine had clinically relevant worsening of quality of life at end of treatment (255 [58%] of 441 vs 235 [50%] of 475; p=0·011) and at 12 months (114 [34%] of 334 vs 89 [22%] of 401; p<0·001 at 12 months) and had worse quality of life over time (p<0·0001). Detailed toxicity and quality-of-life data were collected from 2115 (48%) of treated patients. The most common grade 3 or higher adverse events in cycles 1-4 were neutropenia (175 [16%]) and fatigue (56 [5%]) of the 1070 patients treated with standard epirubicin, and fatigue (63 [6%]) and infection (34 [3%]) of the 1045 patients treated with accelerated epirubicin. In cycles 5-8, the most common grade 3 or higher adverse events were neutropenia (321 [31%]) and fatigue (109 [11%]) in the patients treated with CMF, and hand-foot syndrome (129 [12%]) and diarrhoea (67 [6%]) in the 1044 patients treated with capcitabine. INTERPRETATION: We found no benefit from increasing the dose density of the anthracycline component of chemotherapy. However, capecitabine could be used in place of CMF without significant loss of efficacy and with improved quality of life. FUNDING: Cancer Research UK, Amgen, Pfizer, and Roche
    • …
    corecore